AU2003279312A1 - Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases - Google Patents
Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseasesInfo
- Publication number
- AU2003279312A1 AU2003279312A1 AU2003279312A AU2003279312A AU2003279312A1 AU 2003279312 A1 AU2003279312 A1 AU 2003279312A1 AU 2003279312 A AU2003279312 A AU 2003279312A AU 2003279312 A AU2003279312 A AU 2003279312A AU 2003279312 A1 AU2003279312 A1 AU 2003279312A1
- Authority
- AU
- Australia
- Prior art keywords
- ensadin
- diagnostic
- gene
- protein
- neurodegenerative diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42073702P | 2002-10-24 | 2002-10-24 | |
EP02023872 | 2002-10-24 | ||
US60/420,737 | 2002-10-24 | ||
EP02023872.1 | 2002-10-24 | ||
PCT/EP2003/011747 WO2004038411A2 (en) | 2002-10-24 | 2003-10-23 | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003279312A8 AU2003279312A8 (en) | 2004-05-13 |
AU2003279312A1 true AU2003279312A1 (en) | 2004-05-13 |
Family
ID=32178669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003279312A Abandoned AU2003279312A1 (en) | 2002-10-24 | 2003-10-23 | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003279312A1 (en) |
WO (1) | WO2004038411A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
JP5486808B2 (en) | 2005-11-30 | 2014-05-07 | アッヴィ・インコーポレイテッド | Monoclonal antibody against amyloid beta protein and use thereof |
PL1954718T3 (en) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
CN104744591B (en) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | Amyloid beta binding proteins |
CN105348387B (en) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | Amyloid beta binding proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
EP1358349A2 (en) * | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
-
2003
- 2003-10-23 AU AU2003279312A patent/AU2003279312A1/en not_active Abandoned
- 2003-10-23 WO PCT/EP2003/011747 patent/WO2004038411A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004038411A2 (en) | 2004-05-06 |
WO2004038411A3 (en) | 2004-06-17 |
AU2003279312A8 (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003239531A1 (en) | Protein cages for the delivery of medical imaging and therapy | |
AU2002327792A1 (en) | Diagnosis and treatment of diseases caused by mutations in cd72 | |
AU2003268531A1 (en) | Materials and methods for treatment of allergic diseases | |
AU2003267532A1 (en) | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF Alpha-SYNUCLEIN-RELATED DISEASES | |
AU2003246380A1 (en) | Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases | |
AU2003209150A1 (en) | Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases | |
AU2003260301A1 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
AU2003279312A1 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
AU2003246592A1 (en) | Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases | |
AU2003278497A1 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
AU2002364501A1 (en) | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer | |
AU2003256447A1 (en) | Treatment of autoimmune skin diseases | |
AU2003222849A1 (en) | Diagnostic and therapeutic use of ensadin-0255 gene and protein for neurodegenerative diseases | |
AU2003224080A1 (en) | Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases | |
AU2003224095A1 (en) | Diagnostic and therapeutic use of an atp-binding cassette gene and protein for neurodegenerative diseases | |
AU2003222842A1 (en) | Diagnostic and therapeutic use of ensadin-0138 gene and protein for neurodegenerative diseases | |
AU2003288127A1 (en) | DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE | |
AU2002251367A1 (en) | Proteins and genes for diagnosis and treatment of erbb2-related cancer | |
AU2003242588A1 (en) | Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases | |
AU2003240746A1 (en) | Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases | |
AU2003232200A1 (en) | Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases | |
AU2003294696A1 (en) | Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases | |
AU2003260460A1 (en) | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases | |
AU2002364757A1 (en) | Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases | |
AU2003263036A1 (en) | SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |